APTO - Aptose Biosciences Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
7.01
-0.40 (-5.40%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close7.41
Open7.41
Bid0.00 x 2200
Ask0.00 x 3100
Day's Range6.98 - 7.43
52 Week Range1.81 - 9.25
Volume472,130
Avg. Volume879,681
Market Cap534.919M
Beta (5Y Monthly)1.05
PE Ratio (TTM)N/A
EPS (TTM)-0.55
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.89
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Aptose Biosciences Announces Results of Annual Meeting of Shareholders

      SAN DIEGO and TORONTO, June 02, 2020 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated.

    • GlobeNewswire

      Aptose to Present Early CG-806 Clinical Findings at the 25th Congress of the European Hematology Association

      SAN DIEGO and TORONTO, May 14, 2020 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated.

    • Companies Like Aptose Biosciences (TSE:APS) Can Afford To Invest In Growth
      Simply Wall St.

      Companies Like Aptose Biosciences (TSE:APS) Can Afford To Invest In Growth

      We can readily understand why investors are attracted to unprofitable companies. For example, Aptose Biosciences...

    • GlobeNewswire

      Aptose to Present at 2020 RBC Capital Markets Global Healthcare Virtual Conference

      SAN DIEGO and TORONTO, May 07, 2020 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.

    • Aptose Biosciences (APTO) Q1 2020 Earnings Call Transcript
      Motley Fool

      Aptose Biosciences (APTO) Q1 2020 Earnings Call Transcript

      APTO earnings call for the period ending March 31, 2020.

    • GlobeNewswire

      Aptose Biosciences Establishes New At-The-Market Facility

      Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced that it has entered into an equity distribution agreement (the “Equity Distribution Agreement”) with Piper Sandler and Canaccord Genuity (collectively “Agents”). Under the terms of the Equity Distribution Agreement, the Company may, from time to time, issue and sell through the Agents, common shares of the Company (the “Common Shares”) through “at-the-market” (“ATM”) distributions (the “Offering”) on the Nasdaq Capital Market (“NASDAQ”).

    • GlobeNewswire

      Aptose Reports Results for the First Quarter 2020

      Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced financial results and corporate update for the three months ended March 31, 2020. Based on current operations, we expect that cash on hand and available capital provide the Company with sufficient resources to fund all planned Company operations including research and development into 2022. CG-806 has, thus far, materialized as resilient to the COVID-19 disruptions because of its profile as a safe, orally administered agent directed at critically ill patients with hematologic malignancies and because of the sites chosen for our clinical studies.

    • ACCESSWIRE

      Aptose Biosciences, Inc. to Host Earnings Call

      NEW YORK, NY / ACCESSWIRE / May 5, 2020 / Aptose Biosciences, Inc. (NASDAQ:APTO) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 5, 2020 at 5:00 PM ...

    • Why Aptose Biosciences Stock Sank Today
      Motley Fool

      Why Aptose Biosciences Stock Sank Today

      Investors weren't excited by the biotech's preliminary results from an early-stage clinical study.

    • GlobeNewswire

      Aptose Presents Preliminary Clinical Data on CG-806 at AACR Virtual Annual Meeting 2020

      SAN DIEGO and TORONTO, April 27, 2020 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target.

    • GlobeNewswire

      Aptose Biosciences Files Proxy Statement, Announces Online Only Annual General Meeting

      Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, announced today that it has filed its proxy statement for the 2020 annual general meeting of shareholders. The annual general meeting of Aptose shareholders will be held on June 2, 2020 at 10:00 a.m. Pacific time in an online only format. There will be no physical location for shareholders and duly appointed proxyholders to attend.

    • GlobeNewswire

      Aptose to Release First Quarter Ended March 31, 2020 Financial Results and Hold Conference Call on May 5, 2020

      SAN DIEGO and TORONTO, April 21, 2020 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target.

    • GlobeNewswire

      Aptose Reports Results for the Fourth Quarter and Full Year 2019

      Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced financial results for the year and three months ended December 31, 2019 and reported on corporate developments. Based on current operations, we expect that cash on hand and available capital provide the Company with sufficient resources to fund all planned Company operations including research and development into early 2022.

    • GlobeNewswire

      Aptose to Release Fourth Quarter and Year End December 31, 2019 Financial Results and Hold Conference Call on March 10, 2020

      SAN DIEGO and TORONTO, Feb. 25, 2020 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.

    • Steven Cohen Renews His Interest in Verastem
      GuruFocus.com

      Steven Cohen Renews His Interest in Verastem

      Guru invests in restructuring cancer drug developer Continue reading...

    • GlobeNewswire

      Aptose Biosciences to Host Key Opinion Leader Event Present at BIO CEO & Investor Conference

      SAN DIEGO and TORONTO, Jan. 29, 2020 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.

    • Top Ranked Momentum Stocks to Buy for January 29th
      Zacks

      Top Ranked Momentum Stocks to Buy for January 29th

      Top Ranked Momentum Stocks to Buy for January 29th

    • 5 'Strong Buy' Biotech Stocks to Buy for 2020
      Kiplinger

      5 'Strong Buy' Biotech Stocks to Buy for 2020

      Investors seeking out high growth for their portfolios will often turn to biotech stocks. The biotechnology industry, which has become densely populated as our understanding of living systems and organisms continues to expand, has earned a reputation on Wall Street for its explosive potential ... and high volatility.In contrast to companies in other sectors, the gains and losses in even the best biotech stocks hinge less on earnings results, and more on a few key indicators such as trial-data readouts or verdicts from regulatory agencies. Product approvals unlock vital revenues, so a single positive update can function as a catalyst that propels shares to new highs.Of course, there's a reason risk-averse investors shy away from these stocks: The opposite also holds true.Wall Street pros rightly advise a cautious approach when evaluating the biotechnology industries. We find that monitoring the analyst community can be helpful on a couple fronts: For one, we can see where the pros are putting their faith. Also, analysts can provide much-needed insight into many stocks that get little media coverage, and whose progress can be difficult to gauge unless you're a medical expert.We used TipRanks' Stock Screener tool to comb through hundreds of biotechnology stocks to identify promising picks - ones that have received enough lopsided support from analysts that they earn TipRanks' top Strong Buy consensus rating. Here, we have found five top biotech stocks with overwhelmingly bullish sentiment from the analyst community, and price-growth projections of between 28% and 82%. SEE ALSO: 8 Stock Picks Getting Hit by Coronavirus Fears

    • Is the Options Market Predicting a Spike in Aptose (APTO) Stock?
      Zacks

      Is the Options Market Predicting a Spike in Aptose (APTO) Stock?

      Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.

    • GlobeNewswire

      Aptose Biosciences to Present at Biotech Showcase™ 2020 Conference

      SAN DIEGO and TORONTO, Jan. 07, 2020 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.

    • GlobeNewswire

      Aptose Announces Closing of Public Offering of Common Shares

      Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced the closing of its previously announced underwritten public offering of 18,543,750 common shares (the “Offering”) at the public offering price of US$4.00 per share. The number of shares sold includes the full exercise by the underwriters of their option to purchase additional common shares in the Offering. Gross proceeds from the Offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Aptose, are approximately US$74.2 million.

    • Hedge Funds Have Never Been This Bullish On Aptose Biosciences Inc (APTO)
      Insider Monkey

      Hedge Funds Have Never Been This Bullish On Aptose Biosciences Inc (APTO)

      We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

    • GlobeNewswire

      Aptose Announces Pricing of Public Offering of Common Shares

      Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it priced its previously announced underwritten public offering of 16,125,000 common shares (the “Offering”) at a price of US$4.00 per share. Gross proceeds from the Offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Aptose, are expected to be approximately US$64.5 million. The underwriters have been granted a 30-day option to purchase up to an additional 2,418,750 common shares in the Offering, under the same terms and conditions.

    • Benzinga

      The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO

      The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 16.) Acceleron Pharma Inc (NASDAQ: XLRN ) Amarin ...

    • GlobeNewswire

      Aptose Announces Proposed Public Offering of Common Shares

      Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it has commenced an underwritten public offering of its common shares (the “Offering”). In addition, Aptose intends to grant the Underwriters a 30-day option to purchase up to an additional 15% of the common shares offered in the Offering. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering.